FDA Warning: CAPA & Root Cause Failures
Austin Chuang • April 10, 2026
Discover key GMP violations from the recent FDA Warning Letter to OraLabs Inc. Learn why rigorous Root Cause Analysis is critical for compliance.
FDA Warning: Weaknesses in CAPA & RCA
Executive Summary
A recent Warning Letter from the US Food and Drug Administration (FDA) issued to OraLabs Inc. highlights a persistent and critical issue in GMP inspections: the failure to conduct adequate root cause analysis (RCA) and implement effective CAPA (Corrective and Preventive Actions). The FDA determined that microbiological deviations were frequently invalidated without scientific justification, constituting a clear violation of 21 CFR 211.192.
Causes for deviations were often left unresolved or deemed inconclusive, failing to identify the true origin of the microbiological issues.
Investigations systematically ignored critical influencing factors, including the manufacturing environment, process mechanics, and raw materials.
Despite clear microbiological findings and unclear root causes, product lots were irresponsibly released and placed on the market.
Is Your CAPA Process FDA-Ready?
Persimmon Engineering specializes in robust System Design and Regulatory Compliance. We help pharmaceutical manufacturers establish scientifically sound Root Cause Analysis frameworks and bulletproof CAPA systems that prevent recurrence and satisfy FDA scrutiny.
Optimize Your Compliance StrategyOriginal Source Content
25.03.2026
FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
A recently published Warning Letter from the US Food and Drug Administration (FDA) to OraLabs Inc. (March 2026) once again highlights a recurring pattern in FDA inspections: inadequate root cause analysis (RCA) and the resulting CAPA actions.
At the heart of the findings is a classic GMP violation of 21 CFR 211.192: " Your firm failed to thoroughly investigate any unexplained discrepancy or failure …".The FDA found that investigations carried out into microbiological deviations frequently did not include a sound root cause analysis and that the resulting CAPAs were inadequate.
In several cases, deviations were simply 'invalidated' without sufficient scientific justification.
The following points were particularly highlighted:
- Causes were often inconclusive or left unresolved
- Investigations did not consider all potential influencing factors (e.g. manufacturing process, environment, materials)
- Risks were downplayed, even though clear microbiological findings were available
- Lots were released and placed on the market despite unclear causes
The Warning Letter clearly shows that the FDA continues to scrutinise very closely whether companies carry out systematic and scientifically sound root cause analyses (RCA) and derive effective CAPAs that actually prevent recurrence.
Source: https://www.gmp-compliance.org/gmp-news/fda-warning-letter-highlights-once-again-weaknesses-in-the-capa-process-remain-a-key-gmp-issue
Primary Keywords FDA Warning Letter, CAPA Process, Root Cause Analysis, GMP Violation, 21 CFR 211.192.
Targeted Phrases inadequate root cause analysis in pharma, FDA inspection CAPA actions, microbiological deviation investigations, CFR 211.192 compliance, pharmaceutical lot release risks.
Hashtags #FDACompliance #GMP #CAPA #RootCauseAnalysis #PharmaManufacturing #RegulatoryAffairs #PersimmonEngineering